Skip to content

EBITDA at other companies

TEC
Bio-TechneTECH
Revvity logo
RevvityRVTY
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

$15.9Mebit+
$19.8MDepreciation Depletion & Amortization
=$35.7M

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's EBITDA?
Repligen (RGEN) reported EBITDA of $35.7M in Q1 2026.
How has Repligen's EBITDA changed year-over-year?
Repligen's EBITDA increased by 41.2% year-over-year, from $25.28M to $35.7M.
What is the long-term trend for Repligen's EBITDA?
Over 2 years (2021 to 2023), Repligen's EBITDA has grown at a -19.4% compound annual growth rate (CAGR), from $205.7M to $133.78M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.